ArticleAdvanced therapeutics2021
Lytic polyplex vaccines enhance antigen-specific cytotoxic T cell response through induction of local cell death.
Article in Advanced therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
- Mechanical forces amplify TCR mechanotransduction in T cell activation and function.Applied physics reviews · 2024Review
- Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines.BME frontiers · 2024Article
- Copolymer Micelles: A Focus on Recent Advances for Stimulus-Responsive Delivery of Proteins and Peptides.Pharmaceutics · 2023Review
- A mannosylated polymer with endosomal release properties for peptide antigen delivery.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Development of D-melittin polymeric nanoparticles for anti-cancer treatment.Biomaterials · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endosomolytic vaccine nanocarriers can potentiate cellular immune responses by enhancing cross-presentation. We recently developed a cationic polymer-lytic peptide conjugate (VIPER) that greatly improves endosomal escape and intracellular activity of nucleic acid cargoes; furthermore, we hypothesize that VIPER's unique mechanism of endosomal disruption can increase cytoplasmic delivery of other biomacromolecules (e.g., peptides). Herein, we formulate VIPER as a polyplex subunit vaccine composed of conjugated peptide antigens and electrostatically complexed poly(I:C) nucleic acid adjuvant and evaluate whether the presence of the lytic peptide melittin conjugated to the pH-responsive micelle core improves vaccination outcomes. Although VIPER delivers peptide antigens intracellularly, disrupts endosomes in antigen-presenting cells (APCs)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.